295 related articles for article (PubMed ID: 31745255)
1. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.
Stangl-Kremser J; Suarez-Ibarrola R; Andrea D; Korn SM; Pones M; Kramer G; Marhold M; Krainer M; Enikeev DV; Glybochko PV; Tamandl D; Shariat SF; Baltzer P
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):309-315. PubMed ID: 31745255
[TBL] [Abstract][Full Text] [Related]
2. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
Lee JS; Lee HS; Ha JS; Han KS; Rha KH; Hong SJ; Chung BH; Koo KC
J Urol; 2018 Jul; 200(1):114-120. PubMed ID: 29366641
[TBL] [Abstract][Full Text] [Related]
4. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Sheikhbahaei S; Reyes DK; Rowe SP; Pienta KJ
Prostate; 2021 Feb; 81(2):127-134. PubMed ID: 33259087
[TBL] [Abstract][Full Text] [Related]
5. Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
Hartrampf PE; Mihatsch PW; Seitz AK; Solnes LB; Rowe SP; Pomper MG; Kübler H; Bley TA; Buck AK; Werner RA
J Nucl Med; 2023 Aug; 64(8):1272-1278. PubMed ID: 37290794
[TBL] [Abstract][Full Text] [Related]
6. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients.
Stangl-Kremser J; Mari A; Suarez-Ibarrola R; D'Andrea D; Korn SM; Pones M; Kramer G; Karakiewicz P; Enikeev DV; Glybochko PV; Briganti A; Shariat SF
Urol Oncol; 2020 Jun; 38(6):600.e9-600.e15. PubMed ID: 31953003
[TBL] [Abstract][Full Text] [Related]
7. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
[TBL] [Abstract][Full Text] [Related]
8. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review.
Wu W; Liu X; Chaftari P; Cruz Carreras MT; Gonzalez C; Viets-Upchurch J; Merriman K; Tu SM; Dalal S; Yeung SC
PLoS One; 2015; 10(3):e0122047. PubMed ID: 25822612
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
10. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
11. Body composition predictors of mortality on computed tomography in patients with spinal metastases undergoing surgical treatment.
Bongers MER; Groot OQ; Buckless CG; Kapoor ND; Twining PK; Schwab JH; Torriani M; Bredella MA
Spine J; 2022 Apr; 22(4):595-604. PubMed ID: 34699994
[TBL] [Abstract][Full Text] [Related]
12. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
13. Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
Xu MC; Huelster HL; Hatcher JB; Avulova S; Stocks BT; Glaser ZA; Moses KA; Silver HJ
J Urol; 2021 Mar; 205(3):800-805. PubMed ID: 33080148
[TBL] [Abstract][Full Text] [Related]
14. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
15. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy.
Iwamoto H; Kano H; Shimada T; Naito R; Makino T; Kadomoto S; Yaegashi H; Shigehara K; Izumi K; Kadono Y; Mizokami A
In Vivo; 2021; 35(3):1703-1709. PubMed ID: 33910855
[TBL] [Abstract][Full Text] [Related]
18. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
